gliclazide has been researched along with Diabetic Neuropathies in 9 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)." | 2.38 | Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. ( Brogden, RN; Palmer, KJ, 1993) |
| "The threshold of mechanical hyperalgesia was also significantly elevated." | 1.38 | Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats. ( Ahmed, AA; Al-Rasheed, NM; Attia, HN; Kenawy, SA; Maklad, YA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Alkhudhayri, S | 1 |
| Sajini, R | 1 |
| Alharbi, B | 1 |
| Qabbani, J | 1 |
| Al-Hindi, Y | 1 |
| Fairaq, A | 1 |
| Yousef, A | 1 |
| Yao, H | 2 |
| Feng, J | 2 |
| Zheng, Q | 2 |
| Wei, Y | 2 |
| Yang, G | 1 |
| Feng, W | 2 |
| Wang, S | 1 |
| Avogaro, A | 1 |
| Alp, H | 1 |
| Varol, S | 1 |
| Celik, MM | 1 |
| Altas, M | 1 |
| Evliyaoglu, O | 1 |
| Tokgoz, O | 1 |
| Tanrıverdi, MH | 1 |
| Uzar, E | 1 |
| Attia, HN | 1 |
| Al-Rasheed, NM | 2 |
| Maklad, YA | 1 |
| Ahmed, AA | 1 |
| Kenawy, SA | 1 |
| Wu, YB | 1 |
| Shi, LL | 1 |
| Wu, YJ | 1 |
| Xu, WH | 1 |
| Wang, L | 1 |
| Ren, MS | 1 |
| Palmer, KJ | 1 |
| Brogden, RN | 1 |
| Qiang, X | 1 |
| Satoh, J | 1 |
| Sagara, M | 1 |
| Fukuzawa, M | 1 |
| Masuda, T | 1 |
| Miyaguchi, S | 1 |
| Takahashi, K | 1 |
| Toyota, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559] | Phase 4 | 135 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gliclazide and Diabetic Neuropathies
| Article | Year |
|---|---|
Treating diabetes today with gliclazide MR: a matter of numbers.
Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne | 2012 |
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Drug | 1993 |
1 trial available for gliclazide and Diabetic Neuropathies
| Article | Year |
|---|---|
Protective effect of gliclazide on diabetic peripheral neuropathy through Drp-1 mediated-oxidative stress and apoptosis.
Topics: Animals; Apoptosis; Diabetic Neuropathies; Gliclazide; Hypoglycemic Agents; Male; Neuroprotective Ag | 2012 |
6 other studies available for gliclazide and Diabetic Neuropathies
| Article | Year |
|---|---|
Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats.
Topics: Amides; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Drug T | 2021 |
Comparison of the Effects of Prophylactic and Therapeutic Administrations on Peripheral Neuropathy in Streptozotocin-Diabetic Rats with Gliclazide or Methylcobalamin.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Gliclazide; Hypoglycemic Agents; Ra | 2020 |
The effects of gliclazide, methylcobalamin, and gliclazide+methylcobalamin combination therapy on diabetic peripheral neuropathy in rats.
Topics: Animals; Blood Glucose; Diabetic Neuropathies; Drug Therapy, Combination; Gliclazide; Male; Oxidativ | 2016 |
Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced by streptozosin.
Topics: Animals; Antioxidants; Aryldialkylphosphatase; beta-Glucans; Catalase; Cerebrum; Diabetic Neuropathi | 2012 |
Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide; Curc | 2012 |
Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Gliclaz | 1998 |